Vivos Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Vivos Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Vivos Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$2.65M, a 27.3% increase year-over-year.
  • Vivos Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$12.5M, a 34.8% increase year-over-year.
  • Vivos Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$17.3M, a 30.9% increase from 2022.
  • Vivos Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$25M, a 22.8% decline from 2021.
  • Vivos Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$20.4M, a 69.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$17.3M +$7.74M +30.9% Jan 1, 2023 Dec 31, 2023 10-K/A 2024-07-30
2022 -$25M -$4.65M -22.8% Jan 1, 2022 Dec 31, 2022 10-K/A 2024-07-30
2021 -$20.4M -$8.34M -69.3% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 -$12M -$1.46M -13.8% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 -$10.6M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.